Abstract:Introduction Schizophrenia is a chronic mental disorder and clozapine is an atypical antipsychotic that can be used in treatment-resistant schizophrenia patients. However, treatment-resistant schizophrenia may also include patients with an inadequate response to clozapine. Objectives In our study, we retrospectively analysed the sociodemographic and clinical characteristics of patients receiving clozapine monotherapy and patients receiving clozapine in combination with different antipsychotics. In this way, we aimed to evaluate the factors that influence the response to clozapine. Methods Clozapine monotherapy and clozapine in combination with different antipsychotics were identified by retrospective chart review of patients followed up at the Schizophrenia and Other Psychotic Disorders Outpatient Clinic, Department of Psychiatry, Faculty of Medicine, Selçuk University. Sociodemographic and clinical characteristics were recorded and subjected to statistical analysis. The study was approved by the Ethics Committee of Selçuk University. Results Of the 143 patients whose data were analysed, 60 (42%) were female. The mean age of the patients was 40.2±12.0 years and the mean duration of training was 10.4±4.3 years. 62 patients (43.4%) used long-acting antipsychotics. 90 patients (62.9%) were using clozapine, 52 (36.4%) were using clozapine as monotherapy, 5 (3.5%) were using clozapine together with another oral antipsychotics drug, and 33 (23.1%) were using clozapine together with a long-acting antipsychotic. No statistically significant difference was found when comparing mean age, age at first antipsychotic initiation, age at clozapine initiation and mean clozapine dose between patients using clozapine monotherapy (n=52) and patients using different antipsychotics in combination with clozapine (n=38). When the two groups were compared, a significant difference was found in the mean number of antipsychotics used before starting clozapine and the mean number of hospitalisations, with a lower number in the monotherapy group (3.1±1.4 vs 4.1±2.0, p=0.01 and 2.8±2.2 vs 4.5±3.2, p=0.006, respectively). Conclusions It is important to assess the concept of treatment resistance appropriately in the treatment of schizophrenia patients. The results of our study suggest that starting clozapine treatment promptly in treatment-resistant patients may increase the likelihood that patients will benefit from clozapine and reduce the need for additional treatments. Although our data and criteria for evaluating response to treatment are limited, it is important to draw attention to the clinical results of proceeding in accordance with the guidelines in the treatment of schizophrenia. Evaluating the response to clozapine treatment needs studies with stronger data and larger sample sizes. Disclosure of Interest None Declared

Study on the daily dose and serum concentration of clozapine in psychiatric patients and possible influencing factors of serum concentration

From strict quarantine to an optimized policy: Are we psychologically prepared?

Clozapine dosing patterns and clinical outcomes in patients with treatment resistant schizophrenia

Investigation on clozapine use in patients with schizophrenia

[Population Pharmacokinetics Research of Clozapine in Chinese Schizophrenic Patients].

The effect of clozapine on immune-related biomarkers in schizophrenia patients

Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia

Use of clozapine for the treatment of schizophrenia: findings of the 2006 research on the china psychotropic prescription studies

Clinical and pharmacological factors influencing serum clozapine and norclozapine levels

A brief history of clozapine use in Taiwan

A Comparative Study of Serum Cholinesterase Activity Change and Clinical Effect after Patients Take Clozapine.

Gender, Age, Smoking Behaviour And Plasma Clozapine Concentrations In 193 Chinese Inpatients With Schizophrenia

Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients

Impact of patient-specific factors on clozapine metabolism in individuals with treatment-resistant schizophrenia or schizoaffective disorder

Pro-inflammatory cytokine levels are elevated in female patients with schizophrenia treated with clozapine

Population Pharmacokinetic/Pharmacodynamic Model of Clozapine for Characterizing the Relationship Between Accumulated Exposure and PANSS Scores in Patients with Schizophrenia

Analysis of clinical studies on clozapine from 2012-2022

Clinical study of quetiapine and clozapine in the treatment of schizophrenia

Impact of clozapine monotherapy on gut microbiota and metabolism in people with schizophrenia

[Therapeutic drug monitoring of antipsychotic drugs in routine psychiatric practice]

Retrospective evaluation of sociodemographic and clinical characteristics of patients with schizophrenia receiving clozapine monotherapy and clozapine combined with different antipsychotics